What are your expectations for the timing of a biopharma market recovery?
2. A more optimistic biopharma market sentiment will primarily be catalyzed by an improved macroeconomic outlook, higher levels of M&A and business development activity, and meaningful positive data catalysts
- Over three-quarters of participants (76%) believe that an improved macroeconomic environment – including tempered inflation, consensus on monetary policy and a better global growth outlook – will be the most important catalyst in improving the biopharma landscape.
- This key driver is closely followed by higher levels of M&A and business development activity (58%), and meaningful positive data catalysts (53%).
Which of the following potential catalysts will be the most important in improving the biopharma market outlook? (Select top three)
David Gluckman on the Findings of the 2022 Study
David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare, discusses some of the most notable conclusions from Lazard's 2022 Biopharmaceutical Leaders Study, including the strong degree of optimism among survey respondents regarding the amount of innovation they expect to see in the industry going forward.